---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-027102"
form_type: "8-K/A"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:26:16.078000+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MoonLake AG reports Q1 2022 net loss of $15.9M; business combination with Helix closes raising $134.7M

## Summary
- Net loss of $15.88M for three months ended March 31, 2022; accumulated deficit of $69.5M.
- Cash of $8.8M; current liabilities exceeded current assets by $25.3M as of March 31, 2022.
- Short-term loans of $30M from BVF and Cormorant repaid after Business Combination closed April 5, 2022.
- Business Combination with Helix closed on April 5, 2022, raising $134.7M net of expenses.
- Company is a clinical-stage biopharma focused on Nanobody sonelokimab (SLK) for inflammatory diseases.

## SEC filing metadata
- accession: 0001213900-22-027102
- form_type: 8-K/A
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390022027102/0001213900-22-027102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390022027102/ea159897-8ka1_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-027102
- JSON: https://secwatch.observer/filing/0001213900-22-027102.json
- Plain text: https://secwatch.observer/filing/0001213900-22-027102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.